Kereos

Kereos, Inc. is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of nanoscale drug delivery technologies and molecular imaging agents aimed at the detection and treatment of cancer and cardiovascular diseases. Founded in 1999, Kereos focuses on targeted delivery systems that enhance the effectiveness of therapeutic compounds, including existing drugs and novel candidates, particularly those that are too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001 and KER-1002, both cancer therapeutics utilizing natural products with demonstrated anti-tumor efficacy, and KER-1003, which targets angiogenesis. Additionally, Kereos offers diagnostic applications, such as KER 0001, an imaging platform for detecting angiogenesis. The company is also engaged in developing partnerships with pharmaceutical and imaging firms to advance its molecular imaging systems and cardiovascular disease MRI agents, thereby broadening its impact in the healthcare sector.